Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with ...

Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. NICE noted that clinical trial evidence suggests ...

Your browser does not support the audio element. MG Motor has released the first set of images and details of an all-new ES5 electric SUV. The ES5 will be a global ...

Walgreens plans to close at least 1,200 stores over the next three years as the pharmacy giant seeks to reduce costs and turn around operations under a new leader. One of the largest drugstore ...

Walgreens plans to close 1,200 stores over the next three years, the pharmacy chain said on Tuesday. It's part of the company's plan for a turnaround, as it faces retail competition and lower ...

Citing topline data from its IMforte study, the company said Zepzelca plus Tecentriq cut mortality risk (improved overall survival) with a statistically significant effect compared to Tecentriq ...

MG published the first photos of the ES5, a fully electric SUV for global markets. The ES5 will replace the MG ZS EV, with a larger footprint and modern technology. The MG4-based SUV is powered by ...

Roche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been dashed by a late-stage trial failure looking at the drug in combination with ...

Walgreens is planning to close around 1,200 locations, as the drugstore chain and its rivals struggle to define their role for U.S. shoppers who no longer look to them first for convenience.

Walgreens announced that it will shutter 1,200 stores over the next three years — and 500 locations in 2025 alone — as the drugstore giant seeks to slash $1 billion in costs. The Chicago-based ...